CO2 clue may help doctors treat shock patients better
NCT ID NCT05032521
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether using a CO2-based algorithm to guide treatment of high lactate in patients with acute circulatory failure works better than standard care. 180 adults in intensive care were randomly assigned to either usual treatment or treatment guided by CO2 measurements. The main goal was to see if more patients in the CO2-guided group had a significant drop in lactate levels within 2 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
standard drugs (vasopressors, inotropes, fluids) guided by a CO2-based algorithm
What this could lead to
If successful, this approach could help doctors choose the right treatment for shock patients with high lactate, potentially improving outcomes.
What could go wrong
This is a single-center, Phase 4 trial with 180 participants. The algorithm may not improve lactate clearance or patient outcomes, and results may not apply to all shock patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLACTATEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chu Dijon Bourgogne
Dijon, 21000, France